AUPH Aurinia Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1600620 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.0%
TTM net income YoY303.7%
TTM EPS YoY308.9%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—
Margins
Gross margin90.6%
Operating margin48.6%
Net margin97.7%
FCF margin—
EBITDA margin54.6%
Returns
ROE61.4%
ROA46.4%
ROIC (approx.)34.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage40.36x
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio20.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $283.06M | $235.13M |
| Cost of revenue | $32.66M | $28.25M |
| Gross profit | $250.39M | $206.88M |
| R&D expense | $32.51M | $20.79M |
| SG&A expense | $101.79M | $172.03M |
| Operating income | $104.91M | -$4.69M |
| Interest expense | $4.33M | $4.83M |
| Pretax income | $114.16M | $7.45M |
| Income tax | -$173.04M | $1.70M |
| Net income | $287.20M | $5.75M |
| EBITDA | $124.36M | $14.76M |
| EPS (basic) | 2.14 | 0.04 |
| EPS (diluted) | 2.07 | 0.04 |
| Weighted avg. shares (diluted) | 138.70M | 146.19M |
| Balance sheet | ||
| Cash & equivalents | $80.21M | $83.43M |
| Inventory | $45.69M | $39.23M |
| Current assets | $491.97M | $446.60M |
| PP&E, net | $2.11M | $2.73M |
| Intangibles | $3.76M | $4.36M |
| Total assets | $751.59M | $550.64M |
| Current liabilities | $93.72M | $97.76M |
| Total liabilities | $170.26M | $173.17M |
| Shareholders' equity | $581.33M | $377.48M |
| Shares outstanding | 132.32M | 140.88M |
| Cash flow statement | ||
| Operating cash flow | $135.66M | $44.39M |
| Investing cash flow | -$32.77M | $39.26M |
| Financing cash flow | -$106.11M | -$49.09M |
| Depreciation & amortization | $19.45M | $19.45M |
| Stock-based compensation | $14.68M | $31.60M |
| Share buybacks | $98.16M | $40.24M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.